Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 90

Results For "health"

4562 News Found

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
News | January 04, 2026

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer

Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes


Mabwell’s groundbreaking anti-IL-11 antibody enters Phase II trials for pathological scarring
Clinical Trials | January 04, 2026

Mabwell’s groundbreaking anti-IL-11 antibody enters Phase II trials for pathological scarring

The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring


Elanco scores USDA nod for new canine allergy drug Befrena
News | January 04, 2026

Elanco scores USDA nod for new canine allergy drug Befrena

Elanco expects Befrena to launch in the US in the first half of 2026


BioVarta 2025 puts the spotlight on translating biotech innovation into impact
News | January 04, 2026

BioVarta 2025 puts the spotlight on translating biotech innovation into impact

Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale


CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
News | January 03, 2026

CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half


Govt. issues draft amendment to remove cough syrups from Schedule K
Policy | January 01, 2026

Govt. issues draft amendment to remove cough syrups from Schedule K

Once finalized, cough syrups will no longer be available for over-the-counter sale


China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling
News | January 01, 2026

China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling

The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments


Savara resubmits FDA application for potential treatment in rare lung disease patients
Biopharma | January 01, 2026

Savara resubmits FDA application for potential treatment in rare lung disease patients

The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer


Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
Clinical Trials | January 01, 2026

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates


Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
Biotech | January 01, 2026

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”